Formycon AG (FYB.DE) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

FYB.DE · Stock Price

EUR 19.46-4.89 (-20.08%)

Market Cap: $391.4M

Historical price data

Market Cap: $391.4MPipeline: 4 drugs (1 Phase 3)Founded: 2009HQ: Munich, Germany

Sector Ranking#138 in Biologics / Biosimilars

Overview

Formycon AG is a Germany-based, publicly traded biopharmaceutical company with a strategic focus on developing and commercializing biosimilars and next-generation biologics. The company has successfully transitioned to a commercial-stage entity, with key biosimilars like FYB201 (ranibizumab) approved in Europe, and has secured significant commercial partnerships for its pipeline. Its strategy centers on a robust in-house development platform, strategic licensing deals with global partners for commercialization, and a pipeline targeting high-value immunology and oncology biologics. Formycon aims to create sustainable value by increasing access to affordable biologic medicines while navigating the complex biosimilar regulatory and market landscape.

OphthalmologyImmunologyOncologyEndocrinology

Technology Platform

An integrated platform for biosimilar and next-generation biologic development, encompassing process development, advanced analytical characterization for comparability, formulation, and regulatory strategy.

Pipeline

4

4 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
FYB203 2 mg (0.05 mL of 40 mg/mL)	Age-Related Macular Degeneration	Approved
FYB201 0.5 mg (0.05 mL of 10 mg/mL)	Age-Related Macular Degeneration	Approved
FYB206 + FYB206 + Keytruda	Non Small Cell Lung Cancer	Phase 3
FYB206 + Keytruda	Melanoma, Stage II	Phase 1

Funding History

2

Total raised:$105M

Debt$75MEuropean Investment BankJun 15, 2021

IPO$30MUndisclosedJul 10, 2015

Opportunities

The biosimilars market is expanding rapidly due to patent expiries of blockbuster biologics.

Formycon's targeted pipeline in ophthalmology and immunology addresses multi-billion dollar markets, with its commercial-stage assets and recent patent settlements providing a clear near-term path to revenue generation.

Risk Factors

Key risks include intense price competition in the biosimilar market, potential delays or failures in clinical development or regulatory approval, execution risk from commercialization partners, and ongoing patent litigation challenges that could impede market entry.

Competitive Landscape

Formycon competes with large pharma biosimilar divisions and other biotech developers. Its differentiation lies in a capital-efficient, partnership-focused model and deep technical expertise in analytical comparability, though it faces significant pressure on pricing and market share.